Overview

JYB1907 in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Jemincare